Equity Profile

IDYA

IDEAYA Biosciences, Inc.

Health CareBiotechnology$2.5B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future developments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer. Operating in the health care sector, it aims to address significant unmet medical needs through innovative drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing expectations. The stock reacted with a minor decline of 0.35% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's potential in the oncology space. However, past performance shows mixed results, leading to uncertainty.

Bull Case

If IDEAYA can demonstrate progress in its drug pipeline or show improved financial metrics, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations again or provides weak guidance, it could further erode investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any delays or advancements, as these can significantly impact future revenue and investor sentiment.

How does IDEAYA plan to address its recent earnings misses?

Management's commentary on strategies to improve financial performance will be critical for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential of IDEAYA's pipeline, particularly in targeting specific cancer therapies that could lead to significant breakthroughs.

Supporting Evidence

Despite recent earnings misses, the company's innovative approach to oncology could attract interest from larger pharmaceutical partners.

Options pricing suggests a higher expected move than historical averages, indicating that traders may anticipate a more significant development than currently reflected in the stock price.

Key Risk

If any of the drug candidates show promising results ahead of the earnings report, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether IDEAYA can show progress in its drug development while managing costs effectively.

Bull Confirmed If

Demonstrating a reduction in EPS losses to below -$1.00 could signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats expectations, history suggests a potential stock increase of about 1.2%, confirming bullish sentiment.

In-Line / Cautious

An in-line report with cautious commentary could lead to a muted reaction, as investors weigh future prospects.

Miss

If the company misses expectations, the stock could drop by around 5.0%, reflecting ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trials for key drug candidates.
2Any new partnerships or collaborations that could enhance research capabilities.
3Management's strategy for addressing recent financial performance.
4Insights into market demand for IDEAYA's targeted therapies.
5Future guidance on revenue expectations and operational costs.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug7

PAABMO

Plains All American Pipeline, L.P.

PreviewView

Aug7

ESNTBMO

Company Snapshot

IDEAYA Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and fund future developments.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IDYA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+8281.73%

Avg Stock Reaction

-2.69%

Last Quarter Recap

In Q1-2026, IDEAYA reported an EPS of -$1.11, slightly missing expectations. The stock reacted with a minor decline of 0.35% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's potential in the oncology space. However, past performance shows mixed results, leading to uncertainty.

Bull Case

If IDEAYA can demonstrate progress in its drug pipeline or show improved financial metrics, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to meet expectations again or provides weak guidance, it could further erode investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated timeline for key drug candidates in the pipeline?

The market will closely watch for any delays or advancements, as these can significantly impact future revenue and investor sentiment.

How does IDEAYA plan to address its recent earnings misses?

Management's commentary on strategies to improve financial performance will be critical for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential of IDEAYA's pipeline, particularly in targeting specific cancer therapies that could lead to significant breakthroughs.

Supporting Evidence

Despite recent earnings misses, the company's innovative approach to oncology could attract interest from larger pharmaceutical partners.

Options pricing suggests a higher expected move than historical averages, indicating that traders may anticipate a more significant development than currently reflected in the stock price.

Key Risk

If any of the drug candidates show promising results ahead of the earnings report, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether IDEAYA can show progress in its drug development while managing costs effectively.

Bull Confirmed If

Demonstrating a reduction in EPS losses to below -$1.00 could signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$1.20 would reinforce concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±13.3%

Historical Avg

±4.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±13.3% while IDYA has averaged ±4.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

36.9%

Calls (2K)P/C Ratio: 0.10Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IDEAYA beats expectations, history suggests a potential stock increase of about 1.2%, confirming bullish sentiment.

In-Line / Cautious

An in-line report with cautious commentary could lead to a muted reaction, as investors weigh future prospects.

Miss

If the company misses expectations, the stock could drop by around 5.0%, reflecting ongoing concerns about its performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the clinical trials for key drug candidates.
2Any new partnerships or collaborations that could enhance research capabilities.
3Management's strategy for addressing recent financial performance.
4Insights into market demand for IDEAYA's targeted therapies.
5Future guidance on revenue expectations and operational costs.